Results 111 to 120 of about 2,419 (196)

Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer.

, 1999
The pharmacokinetics of the long-acting beta2-agonist formoterol fumarate, which is a racemate of the (S,S)- and (R,R)-enantiomers were evaluated in 12 healthy (eight male, four female) volunteers after a single inhaled high dose of 120 microg of ...
Kaiser, Guenther, Lecaillon, J B, Morgan, J, Palmisano, M, Della Cioppa, Giovanni   +4 more
core  

Formoterol Fumarate/Roxithromycin [PDF]

, 2020
openaire   +1 more source

A SCINTIGRAPHY STUDY OF BUDESONIDE/GLYCOPYRROLATE/FORMOTEROL FUMARATE IN PATIENTS WITH COPD [PDF]

Chest, 2020
Omar Usmani, Nicolas Roche, Ezanul Abd Wahab, Samuel Israel, Martin Jenkins, Roopa Trivedi, Paul Dorinsky, Magnus Aurivillius   +7 more
openaire   +1 more source

Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study. [PDF]

Int J Chron Obstruct Pulmon Dis, 2023
Strange C, Tkacz J, Schinkel J, Lewing B, Agatep B, Swisher S, Patel S, Edwards D, Touchette DR, Portillo E, Feigler N, Pollack M.   +11 more
europepmc   +1 more source

The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN). [PDF]

Respir Res, 2023
Skloot GS, Guasconi A, Lavon BR, Georges G, De Backer W, Galkin D, Cortellini M, Panni I, Bates JHT.   +8 more
europepmc   +1 more source

Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease

International Journal of COPD, 2013
Teddy Kosoglou,1 James Hubbell,2 Fengjuan Xuan,3 David L Cutler,1 Alan G Meehan,4 Bhavna Kantesaria,5 Bret A Wittmer6,† 1Clinical Pharmacology, 2Exploratory Drug Metabolism, 3Early Development Statistics, 4Medical Communications, 5Drug ...
Kosoglou T, Hubbell J, Xuan F, Cutler DL, Meehan AG, Kantesaria B, Wittmer BA   +6 more
doaj  

Real-life therapeutic effects of beclomethasone dipropionate/formoterol fumarate/glycopyrronium combined triple therapy in patients with chronic obstructive pulmonary disease. [PDF]

Ther Adv Respir Dis, 2023
Pelaia C, Procopio G, Rotundo FL, Deodato MR, Ferrante Bannera A, Tropea FG, Cancelliere A, Vatrella A, Pelaia G.   +8 more
europepmc   +1 more source

Real-World Outcomes across Baseline Risk Profiles in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate in Spain: Insights from the ORESTES Study. [PDF]

Pulm Ther
Alcázar-Navarrete B, Figueira-Gonçalves JM, Blanco Cid N, Bruguera Avila N, Bernabeu Mora R, Fuster Gomila A, Galera Martínez R, García Clemente MM, Granados G, Khadour Khadour H, Márquez-Martín E, Murga Arizabaleta I, Velasco Garrido JL, Corregidor-García C, Fitas E, Sánchez-Covisa J.   +15 more
europepmc   +1 more source

Quantitative Determination of Related Substances in Formoterol Fumarate and Tiotropium in Tiomate Transcaps^® Dry Powder Inhaler [PDF]

Turk J Pharm Sci, 2022
Gondhale PS, Varghese Cheriyan B.
europepmc   +1 more source

Letter to the Editor Regarding "Real-World Outcomes in Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol Fumarate Dehydrate in Spain: ORESTES Study". [PDF]

Adv Ther
Golpe R.
europepmc   +1 more source